Amarin reported $12.54M in EBITDA for its fiscal quarter ending in June of 2025.





Ebitda Change Date
AbbVie USD 3.69B 1.68B Mar/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amarin USD 12.54M 28.57M Jun/2025
AstraZeneca USD 5.16B 510M Jun/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
DBV Technologies USD -45.9M 12.42M Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026